latest news
Covid-19 Interventional Clinical Trials Analysis – 04/05/2020
Since Monday 27th April 2020, a further 217 clinical studies were registered using #coronavirus and its synonyms #coronaviruss, #covid19, #sarscov2, #2019ncov etc. by the end of Monday 4th May, an increase of 25%, ..
read more
Covid-19 Interventional Clinical Trials Analysis – 27/04/2020
Since Monday 20th April 2020, a further 212 clinical trials were registered using #coronavirus and its synonyms #coronaviruss, #covid19, #sarscov2, #2019ncov etc.) by the end of Monday 27th April, taking the current total to 851.
read more
Covid-19 Interventional Clinical Trials Analysis – 20/04/2020
Since Monday 13th April 2020, a further 211 clinical trials were registered using #coronavirus and its synonyms #coronaviruss, #covid19, #sarscov2, #2019ncov etc.) by the end of Monday 20th April, taking the current total to 639.
read moreMedialis recognises the challenges of in-house delivery of medical affairs projects, offering a complete Intelligent End-to-End Medical Affairs delivery vehicle.
INNOVATION
Medialis will analyse your brand plan & create an integrated medical/KOL plan aligned to each CSF. This includes defining strategic assets that need to be developed to meet them.
ASSET GENERATION
Medialis identify and deliver the most appropriate assets...and are best placed to do this.
COMMUNICATION
Medialis can develop and deliver meetings programmes and materials, enabling clear messaging of the key aspects of the medical plan.
innovation
generation
rwe asset publications
communications
How we work
Delivering Real World Evidence... because clinical trials only get you so far.
Medialis recognises the challenges of in-house delivery of medical affairs projects, offering a complete Intelligent End-to-End Medical Affairs delivery vehicle.
Medialis ensures the right strategic asset is generated for the right reason...communicated in the right way.
Medialis Medical Planning and the Multi-Stakeholder Approach
Learn how we can ensure that a medical plan is developed with the full engagement of all stakeholders.
Coordinating and collecting feedback in an efficient way to ensure the items included in the plan are agreed by the internal stakeholders can be a challenge.
Our approach involves using a novel group awareness and consensus methodology to generate and agree, the SWOT, Critical Success Factors (CSFs), Aspirational Statement before we go away and design the tactics themselves.
Medialis, researching and developing new strategies for generating Real World Evidence (RWE)
We at Medialis are excited to share with you details of our RWE original research pipeline.
We’ve committed our own time and resources to research approaches to RWE generation so we can be in the best position to advise our clients of the most appropriate ways to meet their RWE needs.
If you’d like to discuss how we can help in your organisation’s medical planning or RWE generation, please get in touch [email protected]
case study
Medialis generated a strategic manuscript highlighting the importance of weight in the management of Type 2 diabetes
The client promoted a medicine for the treatment of type 2 diabetes, …
Read More
case study
Medialis successfully differentiated AZ (QW) GLP-1 within the GLP-1 class
Medialis devised a method to construct the ‘optimal’ characteristics of a GLP-1 given a range of characteristics from real products.
Read More
case study
Medialis differentiated GSK- ERA within the Endothelin Receptor Antagonist Class
The endothelin receptor class of medicines is used to treat class II and III PAH.
Read More
WHO WE HELP
We work with a number of pharmaceutical companies some of which are based here in the UK. We provide Non-profit services and support in medical communications and medical affairs
